SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Home â–¸ Viewpoints
Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.
Learn the rigorous measures established at Syngene for tissue procurement, iPSC reprogramming, systematic cell banking, inventory management, and quality control of every iPSC batch to maximize drug discovery success.
Learn the simple and complex connections that must be established for successful large molecule bioanalytical sample analysis supporting clinical trials.
Learn the key strategies adopted by leading CDMO Syngene to accelerate the lead to first-in-human (FIH) journey of small molecules for clients.
Learn the challenges in the detection and quantitation of process-related impurities, including nitrosamine and azido impurities, and Syngene’s capabilities and solutions to resolve them.
Learn how Syngene provides in silico and in vitro support for holistic toxicity assessment using Computational & Data Sciences.
Learn the role of biophysics-driven analytical tools in accurately identifying biologics CQAs and analyzing HOS to make the final product efficacious and safe for patients from a regulatory perspective.
Learn the new criteria that have emerged as more important for selecting an outsourcing partner consequent to disruptions caused by the COVID-19 pandemic.
Learn how Syngene is helping pharma companies minimize environmental impact using its Green Chemistry approach to drug development.
Learn how Syngene built a biopharma supply chain that is fast, resilient, and future-proof and, in the process, turned supply chain risks into a competitive advantage.
Learn how Syngene is achieving three to four-fold higher titers of mAbs using its Intensified Fed-Batch process
© 2024. Syngene International Limited